Home › Research › Treatments
Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial
Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, Noguchi M, Nakane H et al.. International journal of psychiatry in medicine, 2011-01-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Objective Down syndrome (DS) patients share certain neuropathological features with Alzheimer disease patients. A randomized, double-blind, placebo-controlled study was performed to investigate the efficacy and safety of donepezil, an Alzheimer disease drug, for DS patients. Method Twenty-one DS patients with severe cognitive impairment were assigned to take donepezil (3 mg daily) or a placebo for 24 weeks, and evaluated for activities in daily lives by concisely modified International Classification of Functioning, Disability and Health (ICF) scaling system. Results ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control. Among the individual functions tested, there was a dramatic improvement in the global mental functions and in specific mental functions. Conclusions Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment.
What this study adds
Evidence grade: High
This is a trial. In this 24-week trial of 21 people with Down syndrome and severe cognitive impairment, those given donepezil showed significantly better scores on a measure of daily functioning than those given placebo, with no adverse effects reported. The authors conclude donepezil may effectively and safely improve overall functioning in this group, though the small number of participants means the findings are preliminary.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kondoh, T., Kanno, A., Itoh, H., Nakashima, M., Honda, R., Kojima, M., et al. (2011). Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. International journal of psychiatry in medicine. https://doi.org/10.2190/pm.41.1.g
Vancouver
Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. International journal of psychiatry in medicine. 2011. doi:10.2190/pm.41.1.g. PMID: 21495523.
BibTeX
@article{kondoh2011-21495523,
author = {Kondoh, T. and Kanno, A. and Itoh, H. and Nakashima, M. and Honda, R. and Kojima, M. and Noguchi, M. and Nakane, H. and others},
title = {{Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial}},
journal = {International journal of psychiatry in medicine},
year = {2011},
doi = {10.2190/pm.41.1.g},
pmid = {21495523},
url = {https://doi.org/10.2190/pm.41.1.g}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control.
- Conclusions Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment.
Why it matters
In this 24-week trial of 21 people with Down syndrome and severe cognitive impairment, those given donepezil showed significantly better scores on a measure of daily functioning than those given placebo, with no adverse effects reported. The authors conclude donepezil may effectively and safely improve overall functioning in this group, though the small number of participants means the findings are preliminary.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 57/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International journal of psychiatry in medicine) |
| Journal's citation record | 1 / 4 | The International Journal of Psychiatry in Medicine: journal h-index 96 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 47 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.8 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Hiroyuki Moriuchi: h-index 40 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Nagasaki University: institution h-index 424 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21495523) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.